DelveInsight’s, “Chronic Kidney Disease Pipeline Insights 2023” report provides comprehensive insights about 76+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Chronic Kidney Disease Pipeline Report
- DelveInsight’s Chronic Kidney Disease pipeline report depicts a robust space with 76+ active players working to develop 80+ pipeline therapies for Chronic Kidney Disease treatment.
- The leading companies working in the Chronic Kidney Disease market include Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies, Inc., MISSION Therapeutics, AceLink Therapeutics, and others.
- Promising Chronic Kidney Disease Pipeline Therapies in the various stages of development roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.
- September 2023: Prokidney announced a study of phase 3 clinical trials for Renal Autologous Cell Therapy (REACT). The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
- September 2023: Bayer announced a study of phase 3 clinical trials for Finerenone (BAY94-8862). The participants will take finerenone or a placebo once a day as tablets by mouth. All of the participants will also continue to take their current medicine for their CKD. The participants will be in the trial for up to about 50 months.
Request a sample and discover the recent advances in Chronic Kidney Disease Treatment Drugs @ Chronic Kidney Disease Pipeline Report
In the Chronic Kidney Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Chronic Kidney Disease Overview
Chronic Kidney Disease is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease.
Find out more about Chronic Kidney Disease Therapeutics Assessment @ Chronic Kidney Disease Preclinical and Discovery Stage Products
Chronic Kidney Disease Emerging Drugs Profile
- KBP-5074: KBP Biosciences
- Ziltivekimab: Novo Nordisk
- US-APR2020: Kibow Pharma
- DM199: DiaMedica Therapeutics
- AL-01211: AceLink Therapeutics
Chronic Kidney Disease Pipeline Therapeutics Assessment
There are approx. 76+ key companies which are developing the Chronic Kidney Disease therapies. The Chronic Kidney Disease companies which have their Chronic Kidney Disease drug candidates in the most advanced stage, i.e. phase III include, KBP Biosciences.
Learn more about the emerging Chronic Kidney Disease Pipeline Therapies @ Chronic Kidney Disease Clinical Trials Assessment
Scope of the Chronic Kidney Disease Pipeline Report
- Coverage- Global
- Chronic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Chronic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Chronic Kidney Disease Companies- Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies, Inc., MISSION Therapeutics, AceLink Therapeutics, and others.
- Chronic Kidney Disease Pipeline Therapies- Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.
Dive deep into rich insights for new drugs for Chronic Kidney Disease Treatment, Visit @ Chronic Kidney Disease Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Chronic Kidney Disease: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Chronic Kidney Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- KBP-5074: KBP Biosciences
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- DM199: DiaMedica Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AL-01211: AceLink Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- SCO-116: Scohia Pharma
- Drug profiles in the detailed report…..
- Inactive Products
- Chronic Kidney Disease Key Companies
- Chronic Kidney Disease Key Products
- Chronic Kidney Disease- Unmet Needs
- Chronic Kidney Disease- Market Drivers and Barriers
- Chronic Kidney Disease- Future Perspectives and Conclusion
- Chronic Kidney Disease Analyst Views
- Chronic Kidney Disease Key Companies
- Appendix
For further information on the Chronic Kidney Disease Pipeline therapeutics, reach out to Chronic Kidney Disease Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking